Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Silence Therapeutics (SLN) Receivables (2019 - 2025)

Silence Therapeutics' Receivables history spans 7 years, with the latest figure at $28000.0 for Q3 2025.

  • For Q3 2025, Receivables changed N/A year-over-year to $28000.0; the TTM value through Sep 2025 reached $28000.0, changed N/A, while the annual FY2024 figure was $972000.0, 242.75% up from the prior year.
  • Receivables for Q3 2025 was $28000.0 at Silence Therapeutics, down from $85000.0 in the prior quarter.
  • Across five years, Receivables topped out at $1.1 million in Q4 2022 and bottomed at $28000.0 in Q3 2025.
  • The 5-year median for Receivables is $282982.6 (2023), against an average of $418343.4.
  • The largest annual shift saw Receivables crashed 98.85% in 2021 before it surged 243.48% in 2024.
  • A 5-year view of Receivables shows it stood at $446191.5 in 2021, then soared by 140.53% to $1.1 million in 2022, then crashed by 73.63% to $282982.6 in 2023, then soared by 243.48% to $972000.0 in 2024, then tumbled by 97.12% to $28000.0 in 2025.
  • Per Business Quant, the three most recent readings for SLN's Receivables are $28000.0 (Q3 2025), $85000.0 (Q2 2025), and $41000.0 (Q1 2025).